(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 14.28% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.54%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Cytosorbents's revenue in 2025 is $34,535,466.On average, 2 Wall Street analysts forecast CTSO's revenue for 2025 to be $2,431,787,004, with the lowest CTSO revenue forecast at $2,369,802,732, and the highest CTSO revenue forecast at $2,493,771,276. On average, 2 Wall Street analysts forecast CTSO's revenue for 2026 to be $2,781,152,902, with the lowest CTSO revenue forecast at $2,665,949,810, and the highest CTSO revenue forecast at $2,896,355,994.
In 2027, CTSO is forecast to generate $3,265,757,212 in revenue, with the lowest revenue forecast at $3,265,757,212 and the highest revenue forecast at $3,265,757,212.